CLINICAL NEWS
use of targeted therapies.”
It is not yet known whether ALK inhibitors will have the same effect on ALKpositive leukemia cells in clinical practice,
nor whether the unselected prevalence
of such lesions would be similarly low in
clinical practice. ●
REFERENCE
Maxson JE, Davare MA, Luty SB, et al. Therapeutically targetable ALK mutations in leukemia. Cancer Res. 2015;75:2146-50.
High Immunoglobulin E Levels:
A Cause for Concern in Cancer Risk?
While